ZKAB001 5mg/kg

DRUG4 trials

Sponsors

Lee's Pharmaceutical Limited

Conditions

Biliary Tract CancerCervical CancerOsteosarcomaUrothelial Carcinoma

Phase 1

A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma

Lee's Pharmaceutical LimitedOsteosarcoma

Start: 2018-10-10End: 2023-06-23Target: 15Updated: 2018-09-26

A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer

Lee's Pharmaceutical LimitedCervical Cancer

Start: 2018-08-16End: 2022-10-15Target: 101Updated: 2021-05-13

A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma

Lee's Pharmaceutical LimitedUrothelial Carcinoma

Start: 2018-10-10End: 2023-06-23Target: 15Updated: 2018-09-26

A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer

Lee's Pharmaceutical LimitedBiliary Tract Cancer

Start: 2021-02-01End: 2023-12-01Target: 10Updated: 2022-01-11

Related Papers

Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

Clinical Cancer Research2022-09-2227 citations

Efficacy and safety of the anti–PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: Results from the phase I dose-escalation and expansion study.

Journal of Clinical Oncology2022-06-012 citations

O014/#828 Efficacy and safety of socazolimab in recurrent or metastatic cervical cancer: results from the phase I trial followed by an expansion study

2021-11-01